Burden of illness of hepatitis C from a managed care organization perspective

Edward P Armstrong, Scott L. Charland

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: The objectives of this study were to: (1) determine the total hepatitis C virus (HCV)-related and total healthcare costs (HCV plus other co-morbidities) of patients with HCV in a managed care organization; (2) determine total healthcare costs of HCV patients with and without a human immunodeficiency virus (HIV) infection as a co-morbidity. Methods: The study design was a retrospective analysis of a medical and pharmacy claims database of patients diagnosed with HCV in a 325 000 member managed care organization. Patients diagnosed with HCV and 12 months of continuous eligibility in the managed care organization from January 1997 through December 1999 were included in the study. The main outcome measures of the study were the total healthcare costs and HCV-related healthcare costs and the impact of HIV as a co-morbidity on these costs. Results: The study identified 614 patients meeting the inclusion criteria. The study population was 58% male and had a mean age of 46 (± 10.6)years. In patients receiving interferon-α, their median total healthcare costs exceeded $4600 and the median HCV-related costs exceeded $2470. The total healthcare costs of HCV patients with HIV as a co-morbidity were significantly larger than patients without this co-morbidity. Conclusion: HCV represents a very important disease to managed care organizations. Patients with this disease require costly drug therapies and consume significant health care resources. Additional research is needed to more fully characterize future clinical and economic outcomes as new agents become available.

Original languageEnglish (US)
Pages (from-to)671-679
Number of pages9
JournalCurrent Medical Research and Opinion
Volume20
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Cost of Illness
Managed Care Programs
Hepatitis C
Hepacivirus
Organizations
Health Care Costs
Morbidity
HIV
Outcome Assessment (Health Care)
Costs and Cost Analysis
Health Resources
Virus Diseases
Interferons
Economics
Databases
Delivery of Health Care
Drug Therapy

Keywords

  • Cost
  • Hepatitis C
  • HIV
  • Managed care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Burden of illness of hepatitis C from a managed care organization perspective. / Armstrong, Edward P; Charland, Scott L.

In: Current Medical Research and Opinion, Vol. 20, No. 5, 05.2004, p. 671-679.

Research output: Contribution to journalArticle

@article{7f1c2f719d1f47f5a9a88ebd80b6a526,
title = "Burden of illness of hepatitis C from a managed care organization perspective",
abstract = "Objectives: The objectives of this study were to: (1) determine the total hepatitis C virus (HCV)-related and total healthcare costs (HCV plus other co-morbidities) of patients with HCV in a managed care organization; (2) determine total healthcare costs of HCV patients with and without a human immunodeficiency virus (HIV) infection as a co-morbidity. Methods: The study design was a retrospective analysis of a medical and pharmacy claims database of patients diagnosed with HCV in a 325 000 member managed care organization. Patients diagnosed with HCV and 12 months of continuous eligibility in the managed care organization from January 1997 through December 1999 were included in the study. The main outcome measures of the study were the total healthcare costs and HCV-related healthcare costs and the impact of HIV as a co-morbidity on these costs. Results: The study identified 614 patients meeting the inclusion criteria. The study population was 58{\%} male and had a mean age of 46 (± 10.6)years. In patients receiving interferon-α, their median total healthcare costs exceeded $4600 and the median HCV-related costs exceeded $2470. The total healthcare costs of HCV patients with HIV as a co-morbidity were significantly larger than patients without this co-morbidity. Conclusion: HCV represents a very important disease to managed care organizations. Patients with this disease require costly drug therapies and consume significant health care resources. Additional research is needed to more fully characterize future clinical and economic outcomes as new agents become available.",
keywords = "Cost, Hepatitis C, HIV, Managed care",
author = "Armstrong, {Edward P} and Charland, {Scott L.}",
year = "2004",
month = "5",
doi = "10.1185/030079904125003485",
language = "English (US)",
volume = "20",
pages = "671--679",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Burden of illness of hepatitis C from a managed care organization perspective

AU - Armstrong, Edward P

AU - Charland, Scott L.

PY - 2004/5

Y1 - 2004/5

N2 - Objectives: The objectives of this study were to: (1) determine the total hepatitis C virus (HCV)-related and total healthcare costs (HCV plus other co-morbidities) of patients with HCV in a managed care organization; (2) determine total healthcare costs of HCV patients with and without a human immunodeficiency virus (HIV) infection as a co-morbidity. Methods: The study design was a retrospective analysis of a medical and pharmacy claims database of patients diagnosed with HCV in a 325 000 member managed care organization. Patients diagnosed with HCV and 12 months of continuous eligibility in the managed care organization from January 1997 through December 1999 were included in the study. The main outcome measures of the study were the total healthcare costs and HCV-related healthcare costs and the impact of HIV as a co-morbidity on these costs. Results: The study identified 614 patients meeting the inclusion criteria. The study population was 58% male and had a mean age of 46 (± 10.6)years. In patients receiving interferon-α, their median total healthcare costs exceeded $4600 and the median HCV-related costs exceeded $2470. The total healthcare costs of HCV patients with HIV as a co-morbidity were significantly larger than patients without this co-morbidity. Conclusion: HCV represents a very important disease to managed care organizations. Patients with this disease require costly drug therapies and consume significant health care resources. Additional research is needed to more fully characterize future clinical and economic outcomes as new agents become available.

AB - Objectives: The objectives of this study were to: (1) determine the total hepatitis C virus (HCV)-related and total healthcare costs (HCV plus other co-morbidities) of patients with HCV in a managed care organization; (2) determine total healthcare costs of HCV patients with and without a human immunodeficiency virus (HIV) infection as a co-morbidity. Methods: The study design was a retrospective analysis of a medical and pharmacy claims database of patients diagnosed with HCV in a 325 000 member managed care organization. Patients diagnosed with HCV and 12 months of continuous eligibility in the managed care organization from January 1997 through December 1999 were included in the study. The main outcome measures of the study were the total healthcare costs and HCV-related healthcare costs and the impact of HIV as a co-morbidity on these costs. Results: The study identified 614 patients meeting the inclusion criteria. The study population was 58% male and had a mean age of 46 (± 10.6)years. In patients receiving interferon-α, their median total healthcare costs exceeded $4600 and the median HCV-related costs exceeded $2470. The total healthcare costs of HCV patients with HIV as a co-morbidity were significantly larger than patients without this co-morbidity. Conclusion: HCV represents a very important disease to managed care organizations. Patients with this disease require costly drug therapies and consume significant health care resources. Additional research is needed to more fully characterize future clinical and economic outcomes as new agents become available.

KW - Cost

KW - Hepatitis C

KW - HIV

KW - Managed care

UR - http://www.scopus.com/inward/record.url?scp=2542479703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542479703&partnerID=8YFLogxK

U2 - 10.1185/030079904125003485

DO - 10.1185/030079904125003485

M3 - Article

VL - 20

SP - 671

EP - 679

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -